Institutional
Foresite Capital Management V, LLC
CIK 0001792206
$271.0M
Reported AUM
9
Positions
Q1 2026
Period
2026-05-15
Filed
The Brief · Foresite Capital Management V, LLC · Q1 2026
AI · grounded in 13F
Foresite Capital Management V, LLC closed its position in Natera, Inc. NTRA, reducing its exposure by $15.4M. The fund established new positions in Eikon Therapeutics, Inc. EIKN for $13.9M, Pharvaris N.V. for $5.4M, and Nurix Therapeutics, Inc. NRIX for $4.1M. Additionally, the fund increased its stake in Hims & Hers Health, Inc. HIMS by 170.2%.
Portfolio · Q1 2026
Top holdings
QoQ vs Q4 2025
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALMS | ALUMIS INC. | $19.06 | -6.52% | 430.92% | 54.96% | $129.9M | 47.94% | +117,647 | +2.0% |
| 2 | CGON | CG Oncology, Inc. | $53.72 | -4.23% | 99.63% | 20.15% | $68.0M | 25.08% | — | HELD |
| 3 | IRON | Disc Medicine, Inc. | $67.00 | -5.78% | 33.95% | -45.13% | $23.9M | 8.83% | +75,000 | +25.1% |
| 4 | HIMS | Hims & Hers Health, Inc. | $26.26 | 0.29% | -53.51% | 231.10% | $15.3M | 5.65% | +465,000 | +170.2% |
| 5 | EIKN | Eikon Therapeutics, Inc. | $8.96 | -8.38% | -38.21% | -15.31% | $14.0M | 5.15% | +1,318,983 | NEW |
| 6 | LYEL | Lyell Immunopharma, Inc. | $12.29 | 2.67% | -6.19% | -95.87% | $9.6M | 3.53% | — | HELD |
| 7 | PHVS | Pharvaris N.V. | $31.09 | -1.71% | 85.28% | 74.96% | $5.5M | 2.02% | +194,125 | NEW |
| 8 | NRIX | Nurix Therapeutics, Inc. | $14.64 | -4.19% | 14.55% | -52.37% | $4.1M | 1.52% | +265,000 | NEW |
| 9 | MAZE | Maze Therapeutics, Inc. | $24.27 | -4.45% | 87.70% | 98.45% | $773K | 0.29% | −60,386 | −70.0% |
| 10 | NTRA | Natera, Inc. | $215.31 | -3.06% | 31.48% | 88.01% | — | — | −67,356 | EXITED |
Source: SEC EDGAR · accession 0001104659-26-062464. 13F discloses long positions only — shorts, foreign equities, and options are excluded.